Arimidex Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Conditions:   Locoregional Recurrence;   Hormone Receptor-positive Breast Cancer;   HER2-negative Breast Cancer Interventions:   Drug: Ribociclib;   Drug: Fulvestrant;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane Sponsors:   Oana Danciu;   Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2022 Category: Research Source Type: clinical trials